HDLs extract lipophilic drugs from cells

J Cell Sci. 2022 Mar 1;135(5):jcs258644. doi: 10.1242/jcs.258644. Epub 2022 Jan 31.

Abstract

High-density lipoproteins (HDLs) prevent cell death induced by a variety of cytotoxic drugs. The underlying mechanisms are however still poorly understood. Here, we present evidence that HDLs efficiently protect cells against thapsigargin (TG), a sarco/endoplasmic reticulum (ER) Ca2+-ATPase (SERCA) inhibitor, by extracting the drug from cells. Drug efflux could also be triggered to some extent by low-density lipoproteins and serum. HDLs did not reverse the non-lethal mild ER stress response induced by low TG concentrations or by SERCA knockdown, but HDLs inhibited the toxic SERCA-independent effects mediated by high TG concentrations. HDLs could extract other lipophilic compounds, but not hydrophilic substances. This work shows that HDLs utilize their capacity of loading themselves with lipophilic compounds, akin to their ability to extract cellular cholesterol, to reduce the cell content of hydrophobic drugs. This can be beneficial if lipophilic xenobiotics are toxic but may be detrimental to the therapeutic benefit of lipophilic drugs such as glibenclamide.

Keywords: Cell death; Doxorubicin; Drug efflux; Glibenclamide; HDL; High-density lipoprotein; Rhodamine 123; Staurosporine; Thapsigargin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / metabolism
  • Endoplasmic Reticulum / metabolism
  • Endoplasmic Reticulum Stress
  • Lipoproteins, HDL*
  • Pharmaceutical Preparations*
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics
  • Thapsigargin / pharmacology

Substances

  • Lipoproteins, HDL
  • Pharmaceutical Preparations
  • Thapsigargin
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium